Pendapatan operasional sadurunge ngurangi amortisasi: Surrozen (SRZN)

The EBITDA_Co chart demonstrates the current resilience of Surrozen, Inc. (SRZN), where the parameter value equals 0.00. Surrozen, Inc. (SRZN) is developing the Wnt regenerative platform to combat intestinal and liver pathologies, leveraging support from Boehringer. Revenues are based on grants for researching new therapy methods. Currently, payments from major pharma partners for access to selective modeling form the financial foundation.

Bathi operasional sadurunge ngurangi amortisasi: Surrozen Corp (SRZN) kanggo 23.11.2025 - 11.11.2026

Ringkesan rincian data analitis Surrozen (SRZN)

- rega saham lan target rega konsensus:

Bagan rega Surrozen Inc.|SRZN - Bagan rega target

- indikator kapitalisasi bursa perusahaan:

Kapitalisasi pasar Surrozen|SRZN - Nilai Total Perusahaan

- data ekuitas miturut neraca:

Aset Bersih saben Saham Surrozen|SRZN - Aset Bersih Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku surrozen.com|SRZN - Aset Agregat Perusahaan

- data tingkat utang lan likuiditas finansial:

- indikator profitabilitas perusahaan lan kelipatan valuasi:

SRZN - Bathi resik perusahaan|Prakiraan bathi resik Surrozen, Inc.|SRZN - Koefisien rega marang bathi|Pangali mangsa ngarep rega marang bathi surrozen.com|SRZN - Pangali PEG|Rasio total nilai perusahaan marang bathi operasional sadurunge panyusutan Surrozen|SRZN - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi saben saham sajrone 12 wulan pungkasan Surrozen|SRZN - Bathi resik saben saham (EPS TTM)|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan surrozen.com|SRZN - Wutah bathi resik saben saham ing taun iki|Prakiraan konsensus wutah bathi saben saham kanggo taun ngarep Surrozen, Inc.

Analisis kabeh metrik perusahaan:Surrozen, Inc.

Identifying fundamentally resilient assets requires an analysis of cash flow from operations before depreciation and interest. This metric measures the actual ability to generate cash, which is critical for Surrozen, Inc. (SRZN) due to costly stem cell research and a lack of profitability; therefore, the size of cash EBITDA serves as an indicator of the company's viability amidst high investment risks.

Analisis pesaing Surrozen, Inc.

Mesoblast Pharma - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|LCTX - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Pendapatan operasional sadurunge ngurangi amortisasi Cryo-Cell International CCEL|fibrobiologics.com (FBLG) - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|LGVN - Pendapatan operasional sadurunge ngurangi amortisasi|Bathi operasional sadurunge ngurangi amortisasi BRTX|Bathi operasional EBITDA Creative Medical Technology Holdings Inc.